Health Canada authorizes vaccine clinical trial for Ebola disease caused by the Bundibugyo virus

Imported from official source

Announcement

Safety Classified by Officially

On July 30, 2026, Health Canada authorized Moderna to move forward with a Phase I clinical trial for its candidate mRNA vaccine for Ebola disease caused by the Bundibugyo virus.

August 4, 2026 | Ottawa, Ontario | Health Canada

Ebola disease is a severe illness with a high fatality rate. There is currently no licensed vaccine or treatment for Bundibugyo virus disease, the type of Ebola disease that is causing the current outbreak in the Democratic Republic of the Congo.

On July 30, 2026, Health Canada authorized Moderna to move forward with a Phase I clinical trial for its candidate mRNA vaccine for Ebola disease caused by the Bundibugyo virus. Canada is the second country to authorize a Phase I clinical trial for a Bundibugyo virus vaccine candidate after the U.K.

The clinical trial will assess the candidate vaccine’s safety, determine the right dosage range and identify any side effects in healthy participants. Following this, Moderna would be required to conduct additional clinical trial phases before it could seek approval from Health Canada for the vaccine. Any final submission would need to meet Health Canada’s stringent safety, efficacy and quality standards before the vaccine could be allowed on the Canadian market.

There have been no cases of Ebola disease in Canada. Orthoebolaviruses are transmitted through direct, unprotected contact with the bodily fluids of an infected person exhibiting symptoms (or someone who has died from the disease), as well as through contact with contaminated objects, infected animals.

Clinical trials are conducted to evaluate new drugs and other medical therapies that have the potential to improve people’s lives. A Phase I clinical trial involves testing a candidate therapy on a small group of healthy people to determine its safety, the right dosage range, and side effects.

This is an extract. The publication continues at the source.

Source: Health Canada. Licence

Read the original at the source: https://www.canada.ca/en/health-canada/news/2026/08/health-canada-authorizes-vaccine-clinical-trial-for-ebola-disease-caused-by-the-bundibugyo-virus.html

Officially imported this from Health Canada’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
Health Canada — imported from official source
Official source
https://api.io.canada.ca/io-server/gc/news/en/v2?dept=departmentofhealth&sort=publishedDate&orderBy=desc&publishedDate%3E=2021-07-23&pick=50&format=atom&atomtitle=Health%20Canada ATOM
Imported
October 03, 2026 20:43
Versions
1 recorded
Identity
https://www.canada.ca/en/health-canada/news/2026/08/health-canada-authorizes-vaccine-cl...

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.